Stability and hydrolysis kinetics of spirosuccinimide type inhibitors of aldose reductase in aqueous solution and retardation of their hydrolysis by the target enzyme

Journal of Pharmaceutical Sciences

Volumn 97, Issue 4, 2008, Pages 1468-1483

  Kurono, Masuo ^a   Itogawa, Akira ^a   Noguchi, Hideto ^a   Sanjoba, Mitsugu ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Decarboxylation; pH rate profile; Spirosuccinimide compounds; Stability; Target enzyme interaction

Indexed keywords

2' (4 BROMO 2 FLUOROBENZYL)SPIRO[PYRROLIDIN 3,4'(1'H)PYRROLO[1,2 A]PYRAZINE] 1',2,3',5(2'H)TETRONE; ALDOSE REDUCTASE INHIBITOR; RANIRESTAT; SUCCINIMIDE DERIVATIVE; SX 3030; SX 3202; UNCLASSIFIED DRUG; ALDEHYDE REDUCTASE; ENZYME INHIBITOR; PYRAZINE DERIVATIVE; SPIRO COMPOUND;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL REACTION KINETICS; DECARBOXYLATION; DRUG STABILITY; DRUG STRUCTURE; ENANTIOMER; HYDROLYSIS; PH; STRUCTURE ANALYSIS; CHEMISTRY; DIABETES MELLITUS; DRUG ANTAGONISM; KINETICS; OSMOLARITY; SOLUTION AND SOLUBILITY;

ALDEHYDE REDUCTASE; DIABETES COMPLICATIONS; DRUG STABILITY; ENZYME INHIBITORS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; OSMOLAR CONCENTRATION; PYRAZINES; SOLUTIONS; SPIRO COMPOUNDS;

EID: 43249098128     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21049     Document Type: Article

References (23)

1. Negoro T, Murata M, Ueda S, Fujitani B, Ono Y, Kuromiya A, Komiya M, Suzuki K, Matsumoto J. 1998. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-nuorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a] pyrazine-4-spiro-3'-pyrro-lidine-l,2',3,5'-tetrone (AS-3201) and its congeners. J Med Chem 41:4118-4129.
2. Gonzalez RG, Barnett P, Aguayo J, Cheng HM, Chylack LT, Jr. 1984. Direct measurement of polyol pathway activity in the ocular lens. Diabetes 33:196-199.
3. Lightman S. 1993. Does aldose reductase have a role in the development of the ocular complications of diabetes? Eye 7:238-241.
4. Yabe-Nishimura C. 1998. Aldose reductase in glucose toxicity: A potential target for the prevention of diabetic complications. Pharmacol Rev 50:21-33.
5. Kurono M, Fujiwara I, Yoshida K. 2001. Stereo-specific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase. Biochemistry 40:8216-8226.
6. Bril V, Buchanan RA. 2004. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 27:2369-2375.
7. Bril V, Buchanan RA. 2006. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 29:68-72.
8. Kurono M, Fujii A, Murata M, Fujitani B, Negoro T. 2006. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: A significant role of specific binding by serum albumin in the improved potency and stability. Biochem Pharmacol 71: 338-353.
9. Nishimura C, Yamaoka T, Mizutani M, Yamashita K, Akera T, Tanimoto T. 1991. Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system. Bio-chim Biophys Acta 1078:171-178.
10. Lide DR, editor. 2004. CRC handbook of chemistry and physics. 85th edition. Boca Raton, FL: CRC Press.
11. The parent racemate and Compound 1 exhibit nearly identical molar extinction coefficients around 296 nm because the absorbance around this wavelength is little affected by the presence or absence of the succinimide moiety.
12. Carstensen JT. 1970. Kinetic salt effect in pharmaceutical investigations. J Pharm Sci 59:1140-1143.
13. Some IT, Bogaerts P, Hanus R, Hanocq M, Dubois J. 2000. Improved kinetic parameter estimation in pH-profile data treatment. Int J Pharm 198:39-49.
14. Zuman P, Patel R. 1984. Techniques in organic reaction kinetics. New York: John Wiley and Sons.
15. Hargreaves MK, Pritchard JG, Dave HR. 1970. Cycliccarboxylicmonoirnides. ChemRev70:439-469.
16. Loudon GM. 1991. Mechanistic interpretation of pH-rate profiles. J Chem Educ 68:973-984.
17. Yakatan GJ, Fan T. 1977. Kinetics of hydrolysis of succinimides. Drug Dev Ind Pharm 3:315-338.
18. Garrett ER, Bojarski JT, Yakatan GJ. 1971. Kinetics of hydrolysis of barbituric acid derivatives. J Pharm Sci 60:1145-1154.
19. Khan MN, Khan AA. 1975. Kinetics and mechanism of hydrolysis of succinimide in highly alkaline medium. J Org Chem 40:1793-1794.
20. Clark LW. 1969. The decarboxylation reaction. In: Patai S, editor. The chemistry of carboxylic acids and esters. London: John Wiley and Sons. pp 589-622.
21. Geiger T, Clarke S. 1987. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem 262:785-794.
22. Capasso S, Mazzarella L, Sica F, Zagari A. 1989. Deamidation via cyclic imide in asparaginyl peptides. Pept Res 2:195-200.
23. Malamas MS, Hohman TC, Millen J. 1994. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2- fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4(1H),3'-pyrrol idine]-1,2',3,5'(2H)-tetrone and congeners. 1. J Med Chem 37:2043-2058.